CT screening for lung cancer: update 2005.

Area of Science:

• Oncology
• Radiology
• Public Health

Background:

• Lung cancer screening with low-dose computed tomography (CT) has demonstrated effectiveness.
• The International Early Lung Cancer Action Program (I-ELCAP) provides a standardized screening and diagnostic protocol.
• Assessing the genuine nature and curability of screen-detected lung cancers is crucial for evaluating screening benefits.

Purpose of the Study:

• To evaluate the diagnostic performance and prognostic implications of CT screening for lung cancer.
• To determine the genuineness and curability rates of lung cancers detected through the I-ELCAP regimen.
• To establish the potential for preventing lung cancer mortality through early detection and treatment.

Main Methods:

• Analysis of data from CT screening programs, specifically following the I-ELCAP protocol.
• Pathology review to confirm malignancy based on established criteria (WHO 2004).
• Estimation of cancer genuineness using growth rate data and assessment of curability through preliminary treatment outcomes.

Main Results:

• CT screening work-up is confined to a small percentage of individuals (<15% baseline, <6% repeat screening).
• Over 80% of detected lung cancers are stage I, with most diagnoses occurring during screening.
• Estimated 90% of baseline-diagnosed stage I cancers are genuine, as are nearly all repeat-screened cancers, with over 90% curability.

Conclusions:

• CT screening, particularly following the I-ELCAP regimen, is highly effective in detecting early-stage lung cancer.
• Screen-detected lung cancers are generally genuine and highly curable, suggesting significant mortality reduction potential.
• Individualized lung cancer screening benefits can be estimated based on age and smoking history, supporting widespread adoption.